Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. more
Time Frame | KRON | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.86% | -3.39% | -3.47% |
1-Month Return | 11.78% | -3.25% | -0.29% |
3-Month Return | 3.25% | -11.61% | 4.5% |
6-Month Return | -5.94% | -5.89% | 6.91% |
1-Year Return | -34.93% | 2.65% | 23.79% |
3-Year Return | -93.21% | 0.56% | 28.43% |
5-Year Return | -96.49% | 34.63% | 83.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 3.08M | 6.29M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":49.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 605.00K | 4.87M | 4.08M | 4.46M | 4.92M | [{"date":"2019-12-31","value":12.31,"profit":true},{"date":"2020-12-31","value":98.98,"profit":true},{"date":"2021-12-31","value":83.01,"profit":true},{"date":"2022-12-31","value":90.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (605.00K) | (4.87M) | (4.08M) | (4.46M) | 6.29M | [{"date":"2019-12-31","value":-9.62,"profit":false},{"date":"2020-12-31","value":-77.39,"profit":false},{"date":"2021-12-31","value":-64.9,"profit":false},{"date":"2022-12-31","value":-70.98,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (144.71%) | 100.00% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":-144.71,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 16.82M | 58.04M | 151.40M | 137.12M | 128.12M | [{"date":"2019-12-31","value":11.11,"profit":true},{"date":"2020-12-31","value":38.34,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.57,"profit":true},{"date":"2023-12-31","value":84.62,"profit":true}] |
Operating Income | (16.82M) | (58.04M) | (151.40M) | (137.12M) | (121.83M) | [{"date":"2019-12-31","value":-1681600000,"profit":false},{"date":"2020-12-31","value":-5804400000,"profit":false},{"date":"2021-12-31","value":-15139800000,"profit":false},{"date":"2022-12-31","value":-13711500000,"profit":false},{"date":"2023-12-31","value":-12183000000,"profit":false}] |
Total Non-Operating Income/Expense | 1.40M | (33.39M) | 640.00K | 7.82M | 18.19M | [{"date":"2019-12-31","value":7.69,"profit":true},{"date":"2020-12-31","value":-183.57,"profit":false},{"date":"2021-12-31","value":3.52,"profit":true},{"date":"2022-12-31","value":43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (16.12M) | (88.44M) | (151.08M) | (133.20M) | (112.67M) | [{"date":"2019-12-31","value":-1611700000,"profit":false},{"date":"2020-12-31","value":-8844400000,"profit":false},{"date":"2021-12-31","value":-15107800000,"profit":false},{"date":"2022-12-31","value":-13320400000,"profit":false},{"date":"2023-12-31","value":-11267300000,"profit":false}] |
Income Taxes | (699.00K) | (24.36M) | (1.98M) | (3.91M) | 4.75M | [{"date":"2019-12-31","value":-14.72,"profit":false},{"date":"2020-12-31","value":-512.98,"profit":false},{"date":"2021-12-31","value":-41.64,"profit":false},{"date":"2022-12-31","value":-82.37,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (15.42M) | (64.09M) | (149.10M) | (129.29M) | (117.42M) | [{"date":"2019-12-31","value":-1541800000,"profit":false},{"date":"2020-12-31","value":-6408700000,"profit":false},{"date":"2021-12-31","value":-14910100000,"profit":false},{"date":"2022-12-31","value":-12929300000,"profit":false},{"date":"2023-12-31","value":-11742110500,"profit":false}] |
Income From Continuous Operations | (16.12M) | (88.44M) | (151.08M) | (133.20M) | (119.14M) | [{"date":"2019-12-31","value":-1611700000,"profit":false},{"date":"2020-12-31","value":-8844400000,"profit":false},{"date":"2021-12-31","value":-15107800000,"profit":false},{"date":"2022-12-31","value":-13320400000,"profit":false},{"date":"2023-12-31","value":-11913500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (15.42M) | (64.09M) | (149.10M) | (129.29M) | (112.67M) | [{"date":"2019-12-31","value":-1541800000,"profit":false},{"date":"2020-12-31","value":-6408700000,"profit":false},{"date":"2021-12-31","value":-14910100000,"profit":false},{"date":"2022-12-31","value":-12929300000,"profit":false},{"date":"2023-12-31","value":-11267300000,"profit":false}] |
EPS (Diluted) | - | (5.25) | (2.75) | (2.37) | (1.95) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-525,"profit":false},{"date":"2021-12-31","value":-275,"profit":false},{"date":"2022-12-31","value":-237,"profit":false},{"date":"2023-12-31","value":-195,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
KRON | |
---|---|
Cash Ratio | 8.12 |
Current Ratio | 8.32 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KRON | |
---|---|
ROA (LTM) | -28.28% |
ROE (LTM) | -63.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KRON | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.26 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KRON | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 6.81 |
P/B | 0.52 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.81 |
Kronos Bio Inc (KRON) share price today is $0.968
Yes, Indians can buy shares of Kronos Bio Inc (KRON) on Vested. To buy Kronos Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KRON stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kronos Bio Inc (KRON) via the Vested app. You can start investing in Kronos Bio Inc (KRON) with a minimum investment of $1.
You can invest in shares of Kronos Bio Inc (KRON) via Vested in three simple steps:
The 52-week high price of Kronos Bio Inc (KRON) is $1.6. The 52-week low price of Kronos Bio Inc (KRON) is $0.69.
The price-to-earnings (P/E) ratio of Kronos Bio Inc (KRON) is
The price-to-book (P/B) ratio of Kronos Bio Inc (KRON) is 0.52
The dividend yield of Kronos Bio Inc (KRON) is 0.00%
The market capitalization of Kronos Bio Inc (KRON) is $57.32M
The stock symbol (or ticker) of Kronos Bio Inc is KRON